Skip to content

Exercise and Systemic Lupus Erythematosus

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01515163
Enrollment
90
Registered
2012-01-23
Start date
2010-05-31
Completion date
2016-07-31
Last updated
2016-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Brief summary

The investigators hypothesize that a three-month aerobic exercise training program will positively affect the lipid profile, insulin sensitivity , cytokine profile, the cardiovascular parameters and muscle strength in SLE patients.

Interventions

BEHAVIORALExercise training

Aerobic exercise training, two times a week

Sponsors

University of Sao Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
7 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Age between 7 and 40 years * SLEDAI ≤ 4

Exclusion criteria

* Cardiovascular dysfunction * Rhythm and conduction disorders * Musculoskeletal disturbances * Kidney and pulmonary involvements * Peripheral neuropathy * Use of tobacco * Treatment with lipid-lowering or hypoglycemic drugs * Fibromyalgia * Use of chronotropic or antihypertensive drugs * Physically active subjects

Design outcomes

Primary

MeasureTime frame
Lipid profile - Plasma levels of total cholesterol (mg/dl), VLDL-chol (mg/dl) HDL-chol (mg/dl), LDL-chol (mg/dl), triglycerides (mg/dl), Apolipoprotein AI and AII (mg/dl) and Apolipoprotein B (mg/dl)3 months
Insulin sensitivity as measured by the Hyperinsulinemic-Euglycemic Clamp3 months
Cytokine response - Plasma levels of TNF-α (pg/ml), IL-6 (pg/ml), IFN-type I (pg/ml), IL-10 (pg/ml)and IL-1ra (pg/ml)3 months

Secondary

MeasureTime frameDescription
Cardiovascular parameters3 monthsAerobic capacity, chronotropic function
Muscle Strength3 monthsUpper and Lower-body muscle strength will be assessed by a 1-RM (repetition maximum) protocol

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026